Brent Crude Tops $110 as Middle East Supply Risks Put Energy Traders on Alert
Brent crude rises above $110 as tanker incidents and disrupted infrastructure reports lift fuel futures and raise inflation concerns.
Moderna’s Nasdaq-100 Inclusion Tests Investor Confidence in Its Oncology Pivot
Moderna’s Nasdaq-100 inclusion may bring passive-fund demand as Phase 3 melanoma data puts its oncology pivot under closer scrutiny.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
CoreWeave Credit Stress Deepens as AI Sell-Off Pushes VIX Above 22
CoreWeave’s widening credit stress is colliding with a broader AI sell-off, sending the VIX above 22 and spotlighting fi…
Ascendis Pharma Stock Slips Despite Positive European Opinion for Already-Approved YUVIWEL
ASND shares closed down 0.6% after a positive European opinion for YUVIWEL, highlighting how investors distinguish fresh…
Opus Genetics Wins FDA Approval for Presbyopia Treatment: What IRD Investors Should Watch Next
Opus Genetics received FDA approval for Phentolamine Ophthalmic Solution, creating a potential catalyst as investors ass…
Omeros Stock Breaks Key Support After Second EU Rejection of Narsoplimab
Omeros shares fell below key support after the EMA rejected narsoplimab again, highlighting the split between US approva…
Pfizer's Expanded TUKYSA Approval Strengthens Its Breast Cancer Turnaround Case
TUKYSA’s expanded FDA approval may strengthen Pfizer’s oncology franchise and support its post-pandemic revenue diversif…
Merck and Moderna’s Phase 3 Cancer Vaccine Win Raises Stakes for mRNA Oncology
Merck and Moderna’s positive Phase 3 cancer-vaccine results strengthen the case for mRNA-immunotherapy combinations and …
Halozyme’s $130 Price Target Reiterated After Positive Takeda Trial Data
H.C. Wainwright reiterated its Buy rating and $130 price target for Nasdaq-listed Halozyme after positive Takeda trial r…
FDA Approval Expands Enspryng’s Thyroid Eye Disease Opportunity for Roche-Backed Genentech
The FDA approved Enspryng for thyroid eye disease, giving Genentech and Roche a potential new avenue for specialty pharm…
Proofpoint's $6.3 Billion Varonis Deal Puts Cybersecurity M&A and Arbitrage in Focus
Proofpoint’s $6.3 billion all-cash deal for Varonis puts the $49.75 offer, merger spreads and cybersecurity consolidatio…